• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Exelixis Inc.

    5/15/25 4:05:42 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXEL alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001692954
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    EXELIXIS, INC.
    SEC File Number
    000-30235
    Address of Issuer
    1851 Harbor Bay Parkway
    Alameda
    CALIFORNIA
    94502
    Phone
    (650) 837-7000
    Name of Person for Whose Account the Securities are To Be Sold
    PATRICK JOSEPH HALEY
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    10000469500.0027270828005/15/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common11/15/2021Performance SharesISSUERCheckbox not checked976011/15/2021Not Applicable
    Common02/15/2023Performance SharesISSUERCheckbox not checked24002/15/2023Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    PATRICK JOSEPH HALEY
    1851 Harbor Bay Parkway
    Alameda � CA � 94502
    Common05/14/202510000426800.00
    PATRICK JOSEPH HALEY
    1851 Harbor Bay Parkway
    Alameda � CA � 94502
    Common03/03/202510000388000.00
    PATRICK JOSEPH HALEY
    1851 Harbor Bay Parkway
    Alameda � CA � 94502
    Common02/24/2025526361946579.84

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/15/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/19/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Patrick J Haley

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $EXEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXEL

    DatePrice TargetRatingAnalyst
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    1/27/2025$30.00 → $40.00Equal-Weight → Overweight
    Morgan Stanley
    1/24/2025Outperform → Perform
    Oppenheimer
    12/20/2024$36.00 → $40.00Outperform → Market Perform
    BMO Capital Markets
    12/17/2024$35.00 → $39.00Buy → Neutral
    BofA Securities
    10/16/2024$30.00 → $34.00Outperform
    RBC Capital Mkts
    9/19/2024$30.00Neutral
    UBS
    4/11/2024$25.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $EXEL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

      9/21/23 4:37:02 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

      7/15/22 4:38:40 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

      9/20/21 3:53:29 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/30/24 7:50:14 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      2/22/24 5:08:50 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      11/29/23 4:30:29 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

      – A regulatory decision by the European Medicines Agency is anticipated in 2025 – – In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting – Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. The European Commission (EC), which has the authority to

      6/20/25 6:54:00 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

      – Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – Exelixis, Inc. (NASDAQ:EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as well as data from multiple dose-escalation cohorts from STELLAR-002, will be presented at the 2025 American Society of Clinical Oncology

      5/22/25 5:17:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

      - Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair 45th Annual Growth Stock Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 10:00 a.m. CT / 8:00 a.m. PT on Tuesday, June 3 in Chicago. Jefferies Global Healthcare Conference 2025: Exelixis is scheduled to present at 7:35 a.m. ET / 4:35 a.m. PT on Wednesday, June 4 in New York City.

      5/22/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Eckhardt Sue Gail sold $805,140 worth of shares (18,838 units at $42.74), decreasing direct ownership by 47% to 21,380 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      6/4/25 7:57:38 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wyszomierski Jack L sold $324,683 worth of shares (7,535 units at $43.09), decreasing direct ownership by 2% to 358,882 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      6/4/25 7:57:28 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Johnson David Edward

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      6/2/25 5:22:46 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care